[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356797-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-356797-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","prediction-of-lymphocyte-predominant-breast-cancer-using-microrna-expression-in-cytology-specimens","Prediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens","","Tumor-infiltrating lymphocytes function as prognostic and predictive biomarkers in breast cancer, yet conventional TIL assessment is limited by invasiveness and subjective scoring, reducing clinical reproducibility. This study evaluated whether microRNA (miRNA) expression profiles from fine-needle aspiration cytology can predict lymphocyte-predominant breast cancer (LPBC). Using reverse-transcriptase PCR, six candidate miRNAs were quantified in 56 patients and assessed by ROC analysis and logistic regression.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prediction-of-lymphocyte-predominant-breast-cancer-using-microrna-expression-in-cytology-specimens/356797/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prediction-of-lymphocyte-predominant-breast-cancer-using-microrna-expression-in-cytology-specimens/356797.png","ImageObject",300,407,{"name":42,"@type":43},"Chumphorn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What was the main goal of this study?","Question",{"text":62,"@type":63},"To determine whether microRNA expression profiles from cytology specimens can objectively predict lymphocyte-predominant breast cancer (LPBC).","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How were LPBC and non-LPBC cases defined in the study?",{"text":67,"@type":63},"LPBC refers to tumors where tumor-infiltrating lymphocytes occupy 50% or more of the tumor stroma; the study evaluated 28 LPBC and 28 non-LPBC patients.",{"name":69,"@type":60,"acceptedAnswer":70},"Which miRNAs were evaluated and how was diagnostic performance measured?",{"text":71,"@type":63},"Six candidate miRNAs (miR-30a-3p, miR-187, miR-196b, miR-1247, miR-4485, miR-6510) were quantified by reverse-transcriptase PCR, and diagnostic accuracy was assessed using receiver operating characteristic analysis with logistic regression modeling.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},356797,1790614234,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","DOI: 10. 1002/cncy.70114  \nORIGINAL ARTICLE  \nPrediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens  \nAzusa Kai MD 1  | Koji Arihiro MD, PhD2 | Hideo Shigematsu MD, PhD1 | Yukari Ohue-Uchihata CT, PhD2 | Momoko Nakamura CT2 | Ai Amioka MD, PhD 1 | Shinsuke Sasada MD, PhD1 | Morihito Okada MD, PhD1  \n1Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan 2Department of Anatomical Pathology, Hiroshima University Hospital, Hiroshima, Japan  \nCorrespondence  \nKoji Arihiro, Department of Anatomical Pathology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734- 8551, Japan.  \nEmail: [arihiro@hiroshima-u.ac.jp](arihiro@hiroshima-u.ac.jp)  \nHideo Shigematsu, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734- 8551, Japan.  \nEmail: [shigematu1330@hiroshima-u.ac.jp](shigematu1330@hiroshima-u.ac.jp)  \nAbstract  \nBackground: Tumor-infiltrating lymphocytes are prognostic and predictive biomarkers of breast cancer; however, conventional assessment is hindered by invasiveness and subjective evaluation, limiting clinical reproducibility. This study investigated the utility of microRNA (miRNA) profiles in predicting lymphocytepredominant breast cancer (LPBC).  \nMethods: This study included 56 patients with breast cancer who underwent fineneedle aspiration cytology at the time of diagnosis (28 LPBC and 28 non-LPBC cases). Total RNA was extracted from cytology smear specimens, and the expression levels of six candidate miRNAs (miR-30a-3p, miR-187, miR-196b, miR-1247, miR-4485, and miR-6510) were quantified using reverse-transcriptase polymerase chain reaction. The performance in identifying LPBC was evaluated using receiver operating characteristic curve analysis and logistic regression models.  \nResults: All six miRNAs showed significantly lower expression levels in the LPBC group than in the non-LPBC group (all p \u003C .05). Receiver operating characteristic curve analysis demonstrated moderate to high diagnostic accuracy, with an area under the curve of 0.708 for miR-30a-3p, 0.739 for miR-187, 0.783 for miR-196b, 0.777 for miR-1247, 0.790 for miR-4485, and 0.673 for miR-6510. Multivariate analysis further identified each miRNA as an independent diagnostic predictor for LPBC.  \nConclusions: miRNA profiling of cytologic samples enabled the objective identification of LPBC. These findings suggest that specific miRNA expression patterns reflect the tumor immune microenvironment and can be used to evaluate the status of tumor-infiltrating lymphocytes in breast cancer.  \nKEYWORDS  \nbiomarker, breast cancer, cytology, immune microenvironment, lymphocyte-predominant breast cancer, microRNA, molecular diagnostics, reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR), tumor-infiltrating lymphocytes  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Cancer Cytopathology published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer Cytopathol. 2026;e70114. wi[leyonlinelibrary.com/journal/cncy](leyonlinelibrary.com/journal/cncy- 1 of)[-](leyonlinelibrary.com/journal/cncy- 1 of)[ 1 of](leyonlinelibrary.com/journal/cncy- 1 of) 11  \n[https://doi.org/10.1002/cncy.70114](https://doi.org/10.1002/cncy.70114)  \nINTRODUCTION  \nTumor-infiltrating lymphocytes (TILs) have gained significant attention in various types of cancer as critical indicators for predicting the efficacy of chemotherapy and immunotherapy as well as the overall prognosis.1–3 Specifically, lymphocyte-predominant breast cancer (LPBC), which is defined as cancers in which TILs occu","cbCaipVQg7sKtdZI","https://ap.wps.com/l/cbCaipVQg7sKtdZI","pdf",1788524,11,"English","# Introduction\n## Tumor-infiltrating lymphocytes and LPBC\n## Limitations of conventional biopsy-based TIL assessment\n## Rationale for miRNA-based objective diagnostics\n# Abstract Overview\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What was the main goal of this study?\",\"answer\":\"To determine whether microRNA expression profiles from cytology specimens can objectively predict lymphocyte-predominant breast cancer (LPBC).\"},{\"question\":\"How were LPBC and non-LPBC cases defined in the study?\",\"answer\":\"LPBC refers to tumors where tumor-infiltrating lymphocytes occupy 50% or more of the tumor stroma; the study evaluated 28 LPBC and 28 non-LPBC patients.\"},{\"question\":\"Which miRNAs were evaluated and how was diagnostic performance measured?\",\"answer\":\"Six candidate miRNAs (miR-30a-3p, miR-187, miR-196b, miR-1247, miR-4485, miR-6510) were quantified by reverse-transcriptase PCR, and diagnostic accuracy was assessed using receiver operating characteristic analysis with logistic regression modeling.\"}]","Prediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens | PDF",1790127338,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/730bb903b91e03226b824a62cfc8779f.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04df40a6735fb81bca12caad0dba8db9.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cba5e25a486e2ebfc3a80530bca66e67.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d2e6e415ad4098bf6ce24f238bf75a1.webp",980,1287]